SPONSOR
Beam Therapeutics Inc.
Total Trials
2
Recruiting
2
Phases
Phase 1, Phase 2
Beam Therapeutics Inc. is a clinical research sponsor with 2 registered studies on ClinicalTrials.gov, of which 2 are actively recruiting participants. Research covers conditions including Alpha 1-Antitrypsin Deficiency, Glycogen Storage Disease Type Ia.
The trial portfolio spans Phase 1, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Beam Therapeutics Inc.
How many clinical trials has Beam Therapeutics Inc. sponsored?
ClinicalMetric currently tracks 2 clinical trials sponsored by Beam Therapeutics Inc., of which 2 are actively recruiting participants. These trials cover conditions including Alpha 1-Antitrypsin Deficiency, Glycogen Storage Disease Type Ia. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Beam Therapeutics Inc. research focus on?
Beam Therapeutics Inc. clinical trials span Alpha 1-Antitrypsin Deficiency, Glycogen Storage Disease Type Ia. The research pipeline includes Phase 1, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Beam Therapeutics Inc. clinical trial?
To participate in a Beam Therapeutics Inc. trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Beam Therapeutics Inc. trials with current recruitment status updated daily.
Clinical Trials by Beam Therapeutics Inc.
NCT06389877 Phase 1, Phase 2
Recruiting
A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)
Alpha 1-Antitrypsin Deficiency
NCT06735755 Phase 1, Phase 2
Recruiting
A Phase 1/2, Dose-Exploration Study to Evaluate the Safety and Efficacy of BEAM-301 in Patients With Glycogen Storage Disease Type Ia (GSDIa)
Glycogen Storage Disease Type Ia
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology